Sinopharm Schedules 23 Oct 2026 Board Meeting to Approve Q3 2026 Unaudited Results

Bulletin Express10-19

Sinopharm Group Co. Ltd. has announced that its board of directors will convene on 23 October 2026 in Shanghai to consider and approve the unaudited consolidated results for the three months ended 30 September 2026.

The notice was issued on 19 October 2026 and signed by Chairman Jin Bin. Sinopharm’s board currently comprises two executive directors, eight non-executive directors and five independent non-executive directors, underscoring a diversified governance structure ahead of the quarterly disclosure.

No financial figures were disclosed in the notice; the company will release detailed Q3 2026 performance metrics following the board’s review and approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment